Baxter International Inc. has agreed to acquire Cheetah Medical, a provider of non-invasive hemodynamic monitoring technologies. Cheetah Medical is viewed as a natural adjacency for Deerfield-based Baxter, given Baxter’s leadership in infusion systems and intravenous (IV) solutions, its breadth of knowledge in fluid management and its presence in critical care and IV therapy.
The transaction consists of an upfront cash consideration of $190 million, with potential for an additional $40 million based on clinical and commercial milestones.
“The robust capabilities and innovative monitoring technologies we will gain with the acquisition of Cheetah Medical will be additional strategic growth drivers as we work to eliminate preventable harm and enable personalized therapy for hospitalized patients around the world,” said Baxter’s general manager of medication delivery, David Ferguson, in a statement.
“We are enthusiastic about the opportunity to bring these products to more patients and clinicians and look forward to building upon Cheetah Medical’s expertise and technology to enhance our leadership in medication delivery and critical care.”
Cheetah Medical, headquartered in Boston and Tel Aviv, Israel, was founded in 2000. Today, its technology is available in approximately 30 countries around the world, including the U.S.
Cheetah Medical President and CEO Chris Hutchinson added: “We strongly believe in the power of our technology to help clinicians make more confident and informed treatment decisions in ways that can help improve patient outcomes and enhance healthcare efficiencies.
Becoming part of Baxter will enable us to continue to invest in clinical and commercial initiatives on a global basis, which will help ensure that the right therapy gets to the right patients at the right time.”
The proposed acquisition is expected to close in the fourth quarter of 2019, subject to customary closing conditions. The company expects the acquisition to be immaterial to earnings in 2019 and 2020.
